Treatment of hypertriglyceridemia-induced pancreatitis by pancreatic duct stenting: a retrospective study

Abstract

Abstract Background To evaluate the effectiveness and safety of pancreatic duct (PD) stenting under endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of patients with hypertriglyceridemia-induced pancreatitis ( HTGP ). Methods The clinical data of 84 patients with HTGP admitted to General Hospital of Ningxia Medical University between January 1, 2017, and July 1, 2020, were retrospectively analyzed. Patients were divided into a conservative group (n = 51) and a stent group (n = 33). The complication rate, transfer rate to intensive care unit (ICU), acute physiological and chronic health APACHE II score at 48 h of admission, triglyceride level and duration of enzyme-inhibiting drug use were compared between the two groups. Results A total of 84 patients with HTGP were enrolled, 68 males and 16 females with a mean age of (38.55 ± 9.63) years. The median triglyceride level at admission was 16.40 (11.85–31.33) mmol/L. All 33 patients in the stent group had successful pancreatic duct stent placed, a large amount of mucinous material filling of the pancreatic duct was clearly observed in 16 patients (48%). The incidence of persistent organ failure was higher in patients with this substance in the pancreatic duct [31.25% (5/16) versus 0% (0/17), P < 0.05]. After the treatment, leukocytes, amylase, triglycerides and APACHE II scores of both in conservative and stent group were significantly lower than those before the treatment(P < 0.05). Patients in the stent group had significantly lower APACHE II scores after treatment than those in the conservative group [(4.65 ± 2.63) versus (2.94 ± 1.45), P < 0.05]. The number of days of fasting, length of hospital stay, and duration of enzyme inhibiting drug use were significantly lower in the stent group than in the conservative group (P < 0.05). The incidence of local complications in the stent group was lower than that in the conservative group [0% (0/33) versus 11.76% (6/51), P < 0.05], and the overall complication rate was also significantly lower than that in the conservative group [9.09% (3/33) versus 47.06% (24/51), P < 0.05]. Conclusion PD stent implantation is a safe and effective treatment strategy, which can quickly relieve abdominal pain, reduce hospitalization time and improve prognosis in patients with HTGP. Conclusion Pancreatic duct stenting is a safe and effective treatment strategy as it can rapidly relieve the clinical symptoms, reduce the length of hospital stay and improve the prognosis of patients with HTGP. Trial Registration: This study was registered as a single-centre, retrospective case series at chictr.org.cn.